Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Patrick P J, Phillips"'
Autor:
Vincent K. Chang, Marjorie Z. Imperial, Patrick P. J. Phillips, Gustavo E. Velásquez, Payam Nahid, Andrew Vernon, Ekaterina V. Kurbatova, Susan Swindells, Richard E. Chaisson, Susan E. Dorman, John L. Johnson, Marc Weiner, Erin E. Sizemore, William Whitworth, Wendy Carr, Kia E. Bryant, Deron Burton, Kelly E. Dooley, Melissa Engle, Pheona Nsubuga, Andreas H. Diacon, Nguyen Viet Nhung, Rodney Dawson, Radojka M. Savic, AIDS Clinical Trial Group, Tuberculosis Trials Consortium
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was
Externí odkaz:
https://doaj.org/article/de940f5d4bbc4e00aaa1dfc2d65e721a
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Randomized trials for the treatment of tuberculosis (TB) rely on a composite primary outcome to capture unfavorable treatment responses. However, variability between trials in the outcome definition and estimation methods complica
Externí odkaz:
https://doaj.org/article/342331141aa04ef1a8c6e400a9fe8aa9
Autor:
Allan Musinguzi, Joan R Kasidi, Jillian L Kadota, Fred Welishe, Anne Nakitende, Lydia Akello, Jane Nakimuli, Lynn T Kunihira, Bishop Opira, Yeonsoo Baik, Devika Patel, Amanda Sammann, Christopher A Berger, Hélène E Aschmann, Payam Nahid, Robert Belknap, Moses R Kamya, Margaret A Handley, Patrick P J Phillips, Noah Kiwanuka, Achilles Katamba, David W Dowdy, Adithya Cattamanchi, Fred C Semitala, Anne R Katahoire
Publikováno v:
PLOS Global Public Health, Vol 4, Iss 10, p e0003347 (2024)
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP deliv
Externí odkaz:
https://doaj.org/article/41e77009facc4c0783714fa4d40e15f8
Autor:
Stellah G. Mpagama, Happiness C. Mvungi, Peter M. Mbelele, Hadija H. Semvua, Alphonce A. Liyoyo, Kristen Petros de Guex, Derek Sloan, Gibson S. Kibiki, Martin Boeree, Patrick P. J. Phillips, Scott K. Heysell
Publikováno v:
Pilot and Feasibility Studies, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract Background Adverse drug reactions (ADRs) frequently occur in patients using second-line anti-tuberculosis medicine for treatment of multidrug resistant tuberculosis (MDR-TB). ADRs contribute to treatment interruptions which can compromise tr
Externí odkaz:
https://doaj.org/article/fac1e3f6fde94e79b20253eb7f51782e
Autor:
Fred C. Semitala, Lelia H. Chaisson, David W. Dowdy, Derek T. Armstrong, Bishop Opira, Kyomugisha Aman, Moses Kamya, Patrick P. J. Phillips, Christina Yoon
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-13 (2022)
Abstract Background People living with HIV (PLHIV) have an increased risk of developing active tuberculosis (TB). To reduce the burden of TB among PLHIV, the World Health Organization (WHO) recommends systematic TB screening followed by (1) confirmat
Externí odkaz:
https://doaj.org/article/86aabc4f7a104d0c9acf66b017b3e109
Autor:
Jillian L. Kadota, Allan Musinguzi, Juliet Nabunje, Fred Welishe, Jackie L. Ssemata, Opira Bishop, Christopher A. Berger, Devika Patel, Amanda Sammann, Anne Katahoire, Payam Nahid, Robert Belknap, Patrick P. J. Phillips, Jennifer Namusobya, Moses Kamya, Margaret A. Handley, Noah Kiwanuka, Achilles Katamba, David Dowdy, Fred C. Semitala, Adithya Cattamanchi
Publikováno v:
Implementation Science, Vol 15, Iss 1, Pp 1-12 (2020)
Abstract Background Recently, a 3-month (12-dose) regimen of weekly isoniazid and rifapentine (3HP) was recommended by the World Health Organization for the prevention of tuberculosis (TB) among people living with HIV (PLHIV) on common antiretroviral
Externí odkaz:
https://doaj.org/article/1cf7443c3d484ea7997fb0bc0d11e477
Autor:
Fred C Semitala, Jillian L Kadota, Allan Musinguzi, Juliet Nabunje, Fred Welishe, Anne Nakitende, Lydia Akello, Opira Bishop, Devika Patel, Amanda Sammann, Payam Nahid, Robert Belknap, Moses R Kamya, Margaret A Handley, Patrick P J Phillips, Anne Katahoire, Christopher A Berger, Noah Kiwanuka, Achilles Katamba, David W Dowdy, Adithya Cattamanchi
Publikováno v:
PLoS Medicine, Vol 18, Iss 12, p e1003875 (2021)
BackgroundScaling up shorter regimens for tuberculosis (TB) prevention such as once weekly isoniazid-rifapentine (3HP) taken for 3 months is a key priority for achieving targets set forth in the World Health Organization's (WHO) END TB Strategy. Howe
Externí odkaz:
https://doaj.org/article/7ef8024b3f924c37b7473ac822998ef2
Autor:
Conor D. Tweed, Angela M. Crook, Rodney Dawson, Andreas H. Diacon, Timothy D. McHugh, Carl M. Mendel, Sarah K. Meredith, Lerato Mohapi, Michael E. Murphy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha P. Singh, Melvin Spigelman, Stephen H. Gillespie
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count > 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We investigated the incidence of adverse events and cure rates according to H
Externí odkaz:
https://doaj.org/article/d4f6503cd6b943dbb18e73105c9b0eb8
Autor:
Ekaterina V. Kurbatova, Patrick P. J. Phillips, Susan E. Dorman, Erin E. Sizemore, Kia E. Bryant, Anne E. Purfield, Jessica Ricaldi, Nicole E. Brown, John L. Johnson, Carole L. Wallis, Joseph P. Akol, Oksana Ocheretina, Nguyen Van Hung, Harriet Mayanja-Kizza, Madeleine Lourens, Rodney Dawson, Nguyen Viet Nhung, Samuel Pierre, Yeukai Musodza, Justin Shenje, Sharlaa Badal-Faesen, Stalz Charles Vilbrun, Ziyaad Waja, Lakshmi Peddareddy, Nigel A. Scott, Yan Yuan, Stefan V. Goldberg, Susan Swindells, Richard E. Chaisson, Payam Nahid
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 207:1376-1382
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93c93ee24026cba6988eb4577b950ca4
https://doi.org/10.1164/rccm.202206-1118oc
https://doi.org/10.1164/rccm.202206-1118oc
Autor:
Conor D. Tweed, Angela M. Crook, Evans I. Amukoye, Rodney Dawson, Andreas H. Diacon, Madeline Hanekom, Timothy D. McHugh, Carl M. Mendel, Sarah K. Meredith, Michael E. Murphy, Saraswathi E. Murthy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha P. Singh, Melvin Spigelman, Genevieve H. Wills, Stephen H. Gillespie
Publikováno v:
BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background The incidence and severity of tuberculosis chemotherapy toxicity is poorly characterised. We used data available from patients in the REMoxTB trial to provide an assessment of the risks associated with the standard regimen and two
Externí odkaz:
https://doaj.org/article/87ffe9cc14bf494197dd9d05a700110f